



IFew 1635

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/432,503
		Filing Date	November 2, 1999
		First Named Inventor	Thomas R. Cech, et al.
		Art Unit	1635
		Examiner Name	Jon E. Angell
Total Number of Pages in This Submission		Attorney Docket Number	015389-002611US; 018/063C

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Supplemental Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Notice of Appeal <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Remarks 1. PTO-1449 (2 pages) with copies of 25 references 2. Return receipt postcard		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Geron Corporation		
Signature			
Printed name	J. Michael Schiff		
Date	Mar 28/06	Reg. No.	40,253

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Janine Watson	Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Cech et al.

Filing Date: November 2, 1999

Serial No: 09/432,503

Docket: 015389-002611US; 018/063c

Title: REDUCING TISSUE DAMAGE DUE TO  
IMPAIRED REPLICATION  
USING A VECTOR EXPRESSING  
TELOMERASE REVERSE TRANSCRIPTASE

Art Unit: 1645

Examiner: J. Eric Angell, Ph.D.

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Alexandria VA 22313

Dear Sir,


The information listed in the accompanying form PTO-1449 and provided herewith is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

Applicants believe that no fee is payable with respect to entry and consideration of this IDS and the accompanying information, since there has been no Office Action on the merits since the filing of the last Request for Continued Examination under 37 CFR § 1.114.

However, in the event that the Patent Office determine that a fee is payable with respect to this IDS, the undersigned hereby authorizes the Commissioner to charge the cost of such petitions and other fees due in connection with the filing of these papers to Deposit Account No. 07-1139, referencing the docket number indicated above.

Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
*Telephone: (650) 473-7715*  
*Fax: (650) 473-8654*


March 27, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use Several Sheets if Necessary)

Title: Increasing the Proliferative Capacity of Cells Using Telomerase Reverse Transcriptase  
Inventors: Thomas R. Cech, et al.

Filing Date: November 2, 1999

Group:



## U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
	DA	2004/0147465 A1	05/09/02	07/29/04		Jiang, Xu-Rong, et al.	Treatment of wounds

## GERON CORPORATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Juris-diction	Title	Translation
	DB	WO 2005/000245	01/06/05		Compostions and methods for increasing telomerase activity	
	DC	WO 2005/044179	05/19/05		Formulations containing astagalus extracts and uses thereof	

## OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	DD	Akimo et al., Bypass of Senescence, Immortalization, and Transfprmation of human hematopoietic progenitor pells, Stem Cells, 23:1423 (2005)
	DE	Bergelson et al., The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses, J of Virology, 72(1): 415 (1998)
	DF	Chen et al., Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery, Circ Res., 80(3):327 (1997)
	DG	Fasbender et al., Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro in vivo, J Bio Chem, 272(10): 6479 (1997)
	DH	Giannobile et al., Platelet-derived growth factor (PDGF) gene delivery for application in periodontal tissue engineering, J Periodontol, 72:815 (2001)
	DI	Geron Corporation, Press Release: March 7, 2005 , Geron Announces presentation of data supporting the utility of smalll molecule telomerase activators for HIV/AIDS therapy
	DJ	Harley et al., Telomerase therapeurics for degenerative diseases, Curr Molec Med, 5:29 (2005)
	DK	Havenga et al., Exploiting the natural diversity in adenovirus tropism for therapy and prevention of desease, J of Virology, 76(9):4612 (2002)
	DL	Huang et al., Adenvirus Interaction with distinct integrins mediates separated events in cell entry and gene delivery to hematopoietic cells, J of Virology, 70(7):4502 (1996)
	DM	Ikeda et al. Adenovirus mediated gene delivery to the joints of guinea pigs, J Rheumatol, 25(9):1666 (1998)
	DN	Ilan, Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors, J Clin Invest., 99(5):1098 (1997)
	DO	Katkin et al., Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung, Hum Gene Ther., 8:171 (1997)
	DP	Kawamoto et al., Gene-based therapy for inner ear disease, Noise Health, 3(11):37 (2001)
	DQ	Koizumi et al., Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and v intergrin-binding ablation, J of Virology, 77(24):13062 (2003)
	DR	Lu et al., A model for keratinocyte gene therapy: preclinical and therapeutic considerations, Proc Assoc Am Physicians, 108(2):165 (1996)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)

Docket: 018/063C

U.S.S.N.: 09/432,503

## SUPPLEMENTAL INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(Use Several Sheets if Necessary)

Title: Increasing the Proliferative Capacity of Cells Using Telomerase Reverse Transcriptase  
Inventors: Thomas R. Cech, et al.

Filing Date: November 2, 1999

Group:



	DS	Mehrara et al., Advenovirus-mediated gene therapy of osteoblasts in vitro and in vivo, J Bone Miner Res., 14(8):1290 (1999)
	DT	Miller et al., Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats, Mol Ther. 12(2):321 (2005)
	DU	Philipson et al., Virus-receptor interaction in an adenovirus system, J of Virology, 2(10):1064 (1998)
	DV	Sarin et al., Conditional telomerase induction causes proliferation of hair follicle stem cells, Nature, 436:1048 (2005)
	DW	Scaria et al., Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway, Gene Ther. 4:611 (1997)
	DX	Shah et al., Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance, Circulation, 101:408 (2000)
	DY	Rothmann et al., Heart muscle-specific gene expression using replication defective recombinant adenovirus, Gene Ther., 3:919 (1996)
	DZ	Wierda et al., CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia, Blood, 96(9):2917 (2000)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**